Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

3SBio To Capitalize On Global Biologics Boom, SciClone Delays Key Financial Filing - Chinese Earnings Roundup (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Year-end and Q4 earnings results for Chinese healthcare operators and drug stores are shaped by a challenging environment imposed by China's healthcare reform and increasing drug pricing pressure. In 2010, a rising tide of inflation also increased minimum wages and labor costs across the country and impacted companies' bottom lines. Many firms have resorted to business diversification, innovation and enriched pipelines to sustain a strong growth.

You may also be interested in...



From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step

3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.

From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step

3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.

From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step

SHANGHAI - 3SBio Inc.'s success with a biosimilar of Amgen Inc.'s erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government

Related Content

Latest News
UsernamePublicRestriction

Register

SC077492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel